(Q48149969)

English

Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24135964%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24135964%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

atrial fibrillation

0 references

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24135964%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Monia Marchetti

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24135964%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Silvana Quaglini

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24135964%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Nicola Lucio Liberato

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24135964%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

1 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24135964%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Clinical Drug Investigation

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24135964%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

34

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24135964%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24135964%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

9-17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24135964%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project).

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Predictors of acute hospital costs for treatment of ischemic stroke in an academic center.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

The costs of care in atrial fibrillation and the effect of treatment modalities in Germany

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Current presentation and management of 7148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: the ATA AF study

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Dabigatran versus warfarin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Apixaban versus warfarin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Risk factors for intracerebral hemorrhage in the general population: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Validation of Clinical Classification Schemes for Predicting Stroke

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

The social and economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-centre cost of illness study

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0144-3

21 January 2018

Newly identified events in the RE-LY trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24135964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24135964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke

1 reference

https://pubmed.ncbi.nlm.nih.gov/24135964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of levosimendan in patients with acute heart failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/24135964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/24135964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Clinical and treatment profiles of patients affected by acute coronary syndromes derived from administrative databases in the ASSL 10 Veneto orientale]

1 reference

https://pubmed.ncbi.nlm.nih.gov/24135964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24135964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty

1 reference

https://pubmed.ncbi.nlm.nih.gov/24135964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/24135964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24135964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24135964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24135964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40261-013-0144-3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24135964%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24135964%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48149969&oldid=1579827523"